Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 5/20 | 0.45 |
| ▸ | THRB | P10828 | 5/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2863706 | 0.81 | SLC5A1 (0.49) | THRATHRBSLC5A1SLC5A2ALDH1A1 | |
| SCHEMBL16301967 | 0.81 | NQO1 (0.54) | LTA4HALDH1A1PTPN1 | |
| SCHEMBL2872101 | 0.79 | LTA4H (0.51) | THRATHRBLTA4HALDH1A1PTPN1 | |
| SCHEMBL2867682 | 0.77 | MAPT (0.46) | LTA4HALDH1A1 | |
| SCHEMBL2874053 | 0.77 | THRA (0.52) | THRATHRBSLC5A1SLC5A2ALDH1A1 | |
| SCHEMBL2637650 | 0.73 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL11314220 | 0.72 | PGK1 (0.49) | ALDH1A1 | |
| SCHEMBL2865173 | 0.72 | SLC5A1 (0.50) | THRATHRBSLC5A1SLC5A2ALDH1A1 | |
| SCHEMBL2874055 | 0.72 | SLC5A2 (0.51) | SLC5A1SLC5A2 | |
| SCHEMBL2866968 | 0.72 | THRA (0.47) | THRATHRBSLC5A1SLC5A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691898-B2 | Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| CN-101072783-A | Phosphonic acid derivative and therapeutic agent for disease in which high phosphate level in blood participates | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2007-11-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | NR0B1, NR0B2, PTH1R | THRA 582/4885THRB 544/4885LTA4H 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.